Nice to see Cannaccord do a detailed Analysis
of Mayne Pharma. Although they extended
Tolsura peaking 2 years after Mayne.
They give A Valuation of 75 cents.
Included in their assessment:
1). “Did Not” allow Myring, E4 or Suva in
their explicit forecasts.
2). The Pipeline Component in their valuation
“DOES NOT “ adequately reflect True Market
Value of these Products.
Conservative to the Extreme , but still great
to hear.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.08 |
Change
0.010(0.20%) |
Mkt cap ! $412.7M | |||
| Open | High | Low | Value | Volume |
| $5.13 | $5.15 | $5.08 | $445.2K | 87.01K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 810 | $5.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.15 | 2033 | 2 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| MYX (ASX) Chart |